Fellow Health to Present Groundbreaking Research on Prostate Cancer Biomarkers and Mail-In PVSA Testing at AUA 2025 Fellow Health, a pioneering healthcare company dedicated to advancing male reproductive health through innovative, patient-centered diagnostics, today announced that it will present four…
Contineum Therapeutics Names Dr. Timothy Watkins as Chief Medical Officer and Head of Development, Signaling Strategic Growth in Clinical Pipeline Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company advancing novel treatments for serious central nervous system (CNS) and immunologic…
Medifast Reports First Quarter 2025 Financial Results, Focuses on Revitalizing Growth and Enhancing Wellness Offerings Medifast, a leading health and wellness company known for its clinically supported and coach-guided lifestyle solution, OPTAVIA®, has announced its financial results for the first…
Dyno Therapeutics to Present Cutting-Edge AAV Gene Delivery Data for CNS, Eye, and Muscle at 2025 ASGCT Annual Meeting Dyno Therapeutics, Inc., a pioneer in genetic technologies harnessing the power of artificial intelligence (AI) to revolutionize in vivo gene delivery,…
Obsidian Therapeutics to Present Groundbreaking Preclinical Data on cytoDRiVE® Platform at the 2025 ASGCT Annual Meeting Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to cell and gene therapy through synthetic biology, has announced the acceptance of a…
Sangamo Therapeutics to Highlight Neurology Pipeline Innovations with Nine Presentations at 28th ASGCT Annual Meeting Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company focused on developing transformative therapies for serious neurological conditions, announced that nine of its scientific abstracts…
Capsida Biotherapeutics to Present Broad Pipeline and Platform Advances at ASGCT 2025 Annual Meeting Capsida Biotherapeutics (“Capsida”), a biotechnology company focused on developing targeted gene therapies for serious neurological and systemic disorders, announced today that it will present significant new…
Strand Therapeutics Unveils Groundbreaking Preclinical Data for STX-003, a Programmable mRNA Therapy Targeting Solid Tumors Strand Therapeutics Inc., a biotechnology company pioneering programmable mRNA technology to develop curative therapies for cancer and other serious diseases, has announced the upcoming presentation…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company committed to developing transformative genetic medicines for patients and families affected by rare neurological diseases, has announced its upcoming participation in the 28th Annual Meeting of the American Society for Gene and…
Personalis’ NeXT Personal® Demonstrates 100% Early Detection of Colorectal Cancer Relapses Ahead of Imaging in Interim VICTORI Study Results Presented at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, the findings show that…
Affinia Therapeutics to Present Breakthrough Data on AFTX-201, Novel BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Advancements at ASGCT 2025 Affinia Therapeutics, a pioneering gene therapy company focused on developing potentially curative treatments for severe cardiovascular and neurological diseases, has announced…
Susan G. Komen® Applauds Bipartisan Reintroduction of the Access to Breast Cancer Diagnosis Act to Eliminate Financial Barriers to Life-Saving Imaging Susan G. Komen®, the world’s leading breast cancer organization, has praised a major bipartisan and bicameral effort in Congress…